Authors : Sunday Akagwu Unyene Musa; Edmund Benle Banwat; Nimzing Lohya

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/38tzvpm6

DOI : https://doi.org/10.38124/ijisrt/26aug1441

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Human Parvovirus B19 (B19V) is a significant cause of foetal morbidity and mortality due to its ability to cross the placenta during maternal viraemia. Despite documented high seroprevalence in Nigeria, data on the molecular evidence of vertical transmission risk among pregnant women are limited. Objective: To determine the seroprevalence, DNA detection rate, and associated risk factors for vertical transmission of B19V among pregnant women attending antenatal clinics in North Central Nigeria. Methods: A cross-sectional study was conducted between 2018 and 2022 involving 276 pregnant women recruited from antenatal clinics of three tertiary health centres in Benue, Kogi and Plateau States, North-Central Nigeria. Demographic and clinical data were collected using a structured questionnaire. Participants’ blood samples were analysed for anti-B19V IgG and IgM antibodies using ELISA. A subset of 38 serologically reactive samples was tested for B19V DNA using quantitative polymerase chain reaction. Statistical associations were analysed using SPSS (v26.0) at 95% confidence level. Results: Anti-B19V IgG and IgM antibodies were detected in 12.7% and 7.7% of the pregnant women, respectively. B19V DNA was detected in 55.3% (21/38) of the sero-reactive pregnant women subset across all trimesters. Detection rate was highest in the second trimester. Tribe was marginally associated with both seroprevalence and DNA positivity; and between the number of previous pregnancies and IgG positivity. Conclusion: This study reports serological and molecular evidence of B19V viraemia among pregnant women in North Central Nigeria, with DNA positivity suggesting risk of vertical transmission. Screening for B19V in antenatal care is recommended to prevent adverse foetal outcomes.

Keywords : Parvovirus B19, Vertical Transmission, Pregnancy, Nigeria, Hydrops Foetalis.

References :

1. Akele, R. Y., Abelekum, J. T., Oluboyo, B. O., Akinseye, J. F., Enitan, S. S., Olayanju, O. A., & Akele, E. J. (2021). Prevalence of human parvovirus B19 IgG and IgM antibodies among pregnant women attending antenatal clinic at Federal Teaching Hospital Ido-Ekiti, Nigeria. African Journal of Infectious Diseases, 15(2), 10-15. https://www.ajol.info/index.php/ajid/article/view/211196
2. Bonvicini F, Bua G, Gallinella G. Parvovirus B19 infection in pregnancy—Awareness and opportunities. Clin Microbiol Infect. 2012;18(7):525–533. https://doi.org/10.1111/j.1469-0691.2012.03845.x
3. Brown KE. Parvovirus B19. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 2675–2691.
4. Brown KE, Young NS. Parvovirus B19. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia: Elsevier Saunders; 2006. p. 423–450.
5. Crabol Y, Terrier B, Rozenberg F, Pérignon A, Papo T. Human parvovirus B19 infection. Rev Med Interne. 2017;38(3):189–195. https://doi.org/10.1016/j.revmed.2016.11.009
6. Dittmer, F. P., Guimarães, C. d. M., Peixoto, A. B., Pontes, K. F. M., Bonasoni, M. P., Tonni, G., & Araujo Júnior, E. (2024). Parvovirus B19 infection and pregnancy: Review of the current knowledge. Journal of Personalized Medicine, 14(2), 139. https://doi.org/10.3390/jpm14020139
7. Emiasegen, S. E., Nimzing, L., Adoga, M. P., Ohagenyi, A. Y., & Lekan, R. (2011). Parvovirus B19 Antibodies and correlates of infection in pregnant women attending an Antenatal clinic in central Nigeria. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(2): 227-231, March 2011
8. Enders M, Weidner A, Zoellner I, Searle K, Enders G, Schalasta G. Fetal morbidity and mortality after acute parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenat Diagn. 2004;24(7):513–518. https://doi.org/10.1002/pd.892
9. Gallinella, G., Manaresi, E., & Zuffi, E. (2010). Parvovirus B19 infection in pregnancy. Journal of Clinical Virology, 48(1), 1–8.
10. Gallinella G. Parvovirus B19 achieves tropism to erythroid cells through multiple cellular receptors: A review. Br J Haematol. 2014;165(4):476–486. https://doi.org/10.1111/bjh.12782
11. Gallinella G. Parvovirus B19 infection: An update. Curr Opin Infect Dis. 2014;27(5):415–422. https://doi.org/10.1097/QCO.0000000000000093
12. Gigi, C., & Anumba, D. O. C. (2021). Parvovirus B19 infection in pregnancy: A review. European Journal of Obstetrics & Gynecology and Reproductive Biology, 264, 358–363. https://doi.org/10.1016/j.ejogrb.2021.07.046
13. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15(3):485–505. https://doi.org/10.1128/CMR.15.3.485-505.2002
14. Iyanda, A., Opaleye, O. O., Ojurongbe, O., & Fagbami, A. H. (2013). Seroprevalence of parvovirus B19 IgG and IgM antibodies among pregnant women in Oyo State, Nigeria. Journal of Infection in Developing Countries, 7(12), 946–950. https://doi.org/10.3855/jidc.3157
15. Jegede A, Aminu M, Ella E. Sero-prevalence of IgG antibody to human parvovirus B19 in Kano, Nigeria. Afr J Clin Exp Microbiol. 2014;15(1):1–7. https://doi.org/10.4314/ajcem.v15i1.1
16. Kagan, K. O., Hoopmann, M., Geipel, A., Sonek, J., & Enders, M. (2024). Prenatal parvovirus B19 infection. Archives of Gynecology and Obstetrics, 310, 2363–2371. https://doi.org/10.1007/s00404-024-07644-6.
17. Keramari S, Poutoglidis A, Chatzis S, Keramaris M, Savopoulos C, Kaiafa G. Parvovirus B19-Associated Myocarditis: A Literature Review of Pediatric Cases. Cureus. 2022 Jan 30;14(1):e21726. doi: 10.7759/cureus.21726. PMID: 35251800; PMCID: PMC8886913.
18. Landry ML.2016.Parvovirus B19. Microbiol Spectr4:10.1128/microbiolspec.dmih2-0008-2015.https://doi.org/10.1128/microbiolspec.dmih2-0008-2015
19. Mossong J, Hens N, Friederichs V, et al. Modelling the impact of antibody-dependent enhancement on disease transmission. PLoS One. 2008;3(6):e2440. https://doi.org/10.1371/journal.pone.0002440
20. Mossong J, Hens N, Friederichs V, et al. Model-based analysis of the spread of parvovirus B19 in Europe. Epidemiol Infect. 2008;136(8):1059–1068. https://doi.org/10.1017/S0950268807009178
21. Musa, Sunday A. U.; Prof. Banwat, Edmund B.; Zhakom Ponfa; Rumji, Elisha M.; Yakubu, Rebecca K. and Rufai, Olalekan A. (2013). Risk of Transfusion-Transmitted Human Parvovirus B19 Infection in Anyigba and Lokoja, Kogi State – Nigeria. Iosr Journal Of Pharmacy (e)-ISSN: 2250-3013, (p)-ISSN: 2319-4219 Www.Iosrphr.Org, 3(3):66-70
22. Ogunjimi B, Willem L, Beutels P, Hens N. Integrating social contact and serological data to model the dynamics of parvovirus B19. Sci Rep. 2015;5:11307. https://doi.org/10.1038/srep11307
23. Prasad, S., et al. (2025). Is parvovirus B19 infection upsurge in 2023–2024 associated with adverse pregnancy outcome? Ultrasound in Obstetrics & Gynecology.
24. Puccetti, A., Dolcino, M., Tinazzi, E., Patuzzo, G., & Lunardi, C. (2014). Parvovirus infection and its association with autoimmune diseases. In M. A. Maldonado & D. H. Kono (Eds.), Autoimmunity: From bench to bedside (Chapter 21). Rosario University Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK459466/
25. Qiu, J., Söderlund-Venermo, M., & Young, N. S. (2017). Human Parvoviruses. Clinical microbiology reviews, 30(1), 43–113. https://doi.org/10.1128/CMR.00040-16
26. Rodis JF, Borgida AF, Wilson M, Egan JF, Leo MV, Odibo A, et al. Management of parvovirus infection in pregnancy and outcomes in fetal hydrops associated with parvovirus B19. Am J Obstet Gynecol. 1998;179(3):838-843. https://doi.org/10.1016/S0002-9378(98)70182-2
27. Servant, A., Laperche, S., Lallemand, F., Marinho, V., De Saint Maur, G., Meritet, J. F., & Garbarg-Chenon, A. (2002). Genetic diversity within human erythroviruses: Identification of three genotypes. Journal of Virology, 76(18), 9124-9134. https://doi.org/10.1128/JVI.76.18.9124-9134.2002
28. Servey JT, Reamy BV, Hodge J. Clinical Presentations of Parvovirus B19 Infection. Am Fam Physician. 2007;75(3):373–376.
29. Sharifi Z, Azizi A, Shooshtari MM. Seroprevalence of Parvovirus B19 among young women in Iran. Iran J Microbiol. 2013;5(2):141–144.
30. Sorrenti, S., Deuster, E., D'Antonio, F., Di Mascio, D., & Khalil, A. (2026). Parvovirus B19 infection in pregnancy: Perinatal outcomes derived from a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2026.03.002.
31. Women’s Health and Education Centre (WHEC). Parvovirus B19 Infection in Pregnancy. WHEC Practice Bulletin. 2009. https://www.womenshealthsection.com/content/gyn/gyn010.php3
32. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586–597. https://doi.org/10.1056/NEJMra030840
33. De Jong EP, Walther FJ, Kroes ACM, Oepkes D. Parvovirus B19 infection in pregnancy: New insights and management. Prenat Diagn. 2018;38(6):538–544. https://doi.org/10.1002/pd.5281